Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Moderate and Severe Plaque Psoriasis”

502 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 502 results

Not applicableStudy completedNCT05650060
What this trial is testing

Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Novartis Pharmaceuticals 163
Large-scale testing (Phase 3)Study completedNCT03535194
What this trial is testing

Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Who this might be right for
Psoriasis
Eli Lilly and Company 1,484
Early research (Phase 1)Study completedNCT03058744
What this trial is testing

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

Who this might be right for
Psoriasis
Bausch Health Americas, Inc. 94
Large-scale testing (Phase 3)Study completedNCT01365455
What this trial is testing

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

Who this might be right for
Moderate to Severe Plaque-type Psoriasis
Novartis Pharmaceuticals 738
Large-scale testing (Phase 3)Study completedNCT01729754
What this trial is testing

Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

Who this might be right for
Plaque Psoriasis
Sun Pharmaceutical Industries Limited 1,090
Large-scale testing (Phase 3)Study completedNCT03051217
What this trial is testing

Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Who this might be right for
Moderate to Severe PsoriasisGeneralized Pustular Psoriasis and Erythrodermic Psoriasis
UCB Biopharma S.P.R.L. 127
Not applicableStudy completedNCT01076192
What this trial is testing

Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)

Who this might be right for
Moderate-to-severe Chronic Plaque Psoriasis
AbbVie (prior sponsor, Abbott) 547
Large-scale testing (Phase 3)Study completedNCT02267135
What this trial is testing

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

Who this might be right for
Chronic Scalp Psoriasis
Novartis Pharmaceuticals 102
Large-scale testing (Phase 3)Active Not RecruitingNCT04036435
What this trial is testing

Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

Who this might be right for
Psoriasis
Bristol-Myers Squibb 1,466
Testing effectiveness (Phase 2)Study completedNCT01622348
What this trial is testing

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Who this might be right for
Actively Extending Plaque PsoriasisModerate to Severe Plaque Psoriasis
Idera Pharmaceuticals, Inc. 44
Large-scale testing (Phase 3)Study completedNCT03589885
What this trial is testing

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Novartis Pharmaceuticals 122
Testing effectiveness (Phase 2)Study completedNCT03463187
What this trial is testing

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Who this might be right for
Moderate-to-severe Chronic Plaque Psoriasis
Jiangsu HengRui Medicine Co., Ltd. 211
Testing effectiveness (Phase 2)Ended earlyNCT00954915
What this trial is testing

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

Who this might be right for
Psoriasis
MacroGenics 1
Post-approval studies (Phase 4)Ended earlyNCT00972543
What this trial is testing

Raptiva in Palm and Sole Psoriasis

Who this might be right for
Chronic Plaque Psoriasis
Merck KGaA, Darmstadt, Germany 6
Large-scale testing (Phase 3)Study completedNCT00195676
What this trial is testing

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
Abbott 1,469
Post-approval studies (Phase 4)Study completedNCT04263610
What this trial is testing

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy

Who this might be right for
Plaque Psoriasis
Almirall, S.A. 190
Testing effectiveness (Phase 2)Study completedNCT03230292
What this trial is testing

Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

Who this might be right for
Chronic Plaque Psoriasis
UCB Biopharma SRL 43
Large-scale testing (Phase 3)Study completedNCT03066609
What this trial is testing

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Who this might be right for
Plaque Psoriasis
Novartis Pharmaceuticals 543
Early research (Phase 1)Looking for participantsNCT06888193
What this trial is testing

Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Who this might be right for
Moderate to Severe Plaque PsoriasisPsoriatic ArthritisAxial Spondyloarthritis+1 more
UCB Biopharma SRL 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06875934
What this trial is testing

A Trial Comparing SHR-1139 Injection With Placebo in Patients With Moderate-to-severe Plaque Psoriasis

Who this might be right for
Moderate to Severe Plaque Psoriasis
Guangdong Hengrui Pharmaceutical Co., Ltd 145
Load More Results